The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Benzer Materyaller

• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  Yazar:: Bean, James, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET
  Yazar:: Xu, Lu, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
  Yazar:: Zhang, Nana, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
  Yazar:: Gao, Hong-Fei, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
  Yazar:: Oxnard, Geoffrey R., ve diğerleri
  Baskı/Yayın Bilgisi: (2010)